Lv2
170 积分 2022-09-19 加入
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models
18天前
已完结
Homogeneous multi-payload antibody–drug conjugates
25天前
已完结
Total Synthesis, Mechanism of Action, and Antitumor Efficacy of Camptothecin and Some of its Analogues
28天前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
1个月前
已完结
Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment
2个月前
已完结
[A method of electrophysiological investigation of cardiac and vascular function]
3个月前
已关闭
Product Class 1: Ketene
5个月前
已完结
RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS
5个月前
已完结
Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1
7个月前
已完结
Atropisomeric 4-Phenyl-4H-1,2,4-triazoles as Selective Glycine Transporter 1 Inhibitors
8个月前
已完结
皖公网安备34019202002308
